Objectives To synthesise current evidence for the effects of exenatide and liraglutide on
heart rate, blood pressure and body weight. Design Meta-analysis of available data from …

Diabetes mellitus is one of the most prevalent metabolic disorders that affect people of all
genders, ages, and races. Medicinal herbs have gained wide attention from researchers and …

Many anti-diabetic drugs with different mechanisms of action are now available for treatment
of type 2 diabetes mellitus. Sulfonylureas have been extensively used for treatment of type 2 …

Objective Type 2 diabetes and obesity are pro-inflammatory states associated with
increased risk of cardiovascular disease. Canagliflozin, an SGLT2 inhibitor, demonstrated …

Aim Cardiovascular safety of sulfonylurea has been questioned by some authors. This
article aims at collecting all available data on this issue from randomized trials. Methods A …

Aims To determine the effects of glucagon-like peptide-1 receptor agonists compared with
placebo and other anti-diabetic agents on weight loss in overweight or obese patients with …

Introduction: Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs
have been withdrawn because of their adverse effects. In fact, orlistat is the only available …

Aims: During recent years, two strategies of incretin‐based therapy [glucagon‐like peptide‐1
(GLP‐1) receptor agonism and dipeptidyl peptidase‐4 (DPP‐4) inhibition] have entered the …

Aim: Most guidelines recommend metformin as first‐line therapy in patients with type 2
diabetes. However, the choice of a second‐line drug lacks consistent consensus. We aimed …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin
secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety …